Financing
Stock Issuance Proceeds
Alnylam Pharmaceuticals Stock Issuance Proceeds decreased by 68.4% to $13.16M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 73.3%, from $49.37M to $13.16M.
Analysis
StatementCash Flow Statement
SectionFinancing
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
Metric ID:
proceeds_from_stock_issuanceHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $81.86M | $72.39M | -$201.23M | $27.12M | $22.50M | $153.02M | $56.71M | $42.37M | $49.39M | $24.81M | $30.89M | $25.86M | $132.78M | $108.04M | $36.28M | $49.37M | $81.22M | $77.74M | $41.70M | $13.16M |
| QoQ Change | — | -11.6% | -378.0% | +113.5% | -17.0% | +580.0% | -62.9% | -25.3% | +16.6% | -49.8% | +24.5% | -16.3% | +413.5% | -18.6% | -66.4% | +36.1% | +64.5% | -4.3% | -46.4% | -68.4% |
| YoY Change | — | — | — | — | -72.5% | +111.4% | +128.2% | +56.2% | +119.5% | -83.8% | -45.5% | -39.0% | +168.8% | +335.5% | +17.4% | +90.9% | -38.8% | -28.0% | +14.9% | -73.3% |
Range-$201.23M – $153.02M
CAGR-31.9%
Avg YoY Growth+41.4%
Median YoY Growth+16.2%
Current Streak3 quarters decline
Stock Issuance Proceeds at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's stock issuance proceeds?
- Alnylam Pharmaceuticals (ALNY) reported stock issuance proceeds of $13.16M in Q1 2026.
- How has Alnylam Pharmaceuticals's stock issuance proceeds changed year-over-year?
- Alnylam Pharmaceuticals's stock issuance proceeds decreased by 73.3% year-over-year, from $49.37M to $13.16M.